Home › Pain After Surgery › NCT07689162

Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia

Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia: A Randomized Clinical Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients (≥18 years) undergoing open rhinoplasty of any indication or complexity (e.g., primary, revision, functional, or cosmetic), including autologous grafting of any type (e.g., septal or costal cartilage) or cadaveric grafting.

Exclusion Criteria:

* Chronic pain condition requiring ongoing or scheduled analgesic therapy, or any diagnosis associated with chronic pain (e.g., fibromyalgia, chronic headache/migraine, neuropathic pain, complex regional pain syndrome), long-term opioid use (≥3 months, any agent), allergy or contraindication to local anesthetics, acetaminophen, ibuprofen / NSAIDs, tramadol, ketamine, Medrol (methylprednisolone) dose pack
* Concurrent non-nasal surgery planned

About the study

The purpose of this study is to find out which pain medication is more effective in reducing pain after nose surgery (rhinoplasty). The investigators are looking to find the best treatment to reduce discomfort and improve the healing process for patients having nose surgery.

What is being tested

• Standard Bupivacaine (drug)
• Liposomal Bupivacaine (drug)

Sponsor: Washington University School of Medicine · Participants: 45 · Started: Aug 1, 2026

Contact the study team

• Matthew Wu, MD · Phone: 314-362-0524
• Sara Kukuljan, BS, RN · Phone: 314-362-7563

Official record on ClinicalTrials.gov — NCT07689162

Locations in the U.S.

Conditions

• Pain After Surgery

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.